Identification of SLPI (secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation.
Recently interest has been focused on secretory leucocyte protease inhibitor (SLPI) and its role in immediate hypersensitive reactions, possibly by inhibiting mast cell chymase. The purpose of this investigation was to show whether or not SLPI is produced in mast cells. Double-immunolabelling revealed that SLPI coexists with mast cell tryptase (60%) and chymase (37%). On the other hand, in situ hybridisation studies demonstrated the expression of SLPI mRNA in all mast cells. The differences in results can be attributed to the fact that in situ hybridisation is a more sensitive method than immunohistochemistry. Hence, we conclude that SLPI is produced in human tonsillar mast cells.
Westin
U
U
Department of Otorhinolaryngology, University Hospital of Malmö, University of Lund, Sweden.
Polling
A
A
Ljungkrantz
I
I
Ohlsson
K
K
D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008407:Mast Cells / Q000378:metabolism*; D009297:Nasal Mucosa / Q000166:cytology / Q000378:metabolism; D014066:Palatine Tonsil / Q000166:cytology / Q000378:metabolism; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000378:metabolism*; D012471:Salivary Proteins and Peptides / Q000378:metabolism*; D053481:Secretory Leukocyte Peptidase Inhibitor
D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; C506814:SLPI protein, human; D012471:Salivary Proteins and Peptides; D053481:Secretory Leukocyte Peptidase Inhibitor